Back

One-year follow-up of adefovir dipivoxil treatment in chronic hepatitis B patients

Abstract number: 1733_991

Kurtaran B., Aksu H., Tasova Y., Saltoglu N., Inal A., Candevir A., Seydaoglu G.

Objective: The aim of this study is to evaluate the results of adefovir dipivoxil treatment in hepatitis B e antigen-positive and negative chronic hepatitis B patients. We conducted this study to investigate the efficacy of 48 week treatment with this drug at a dose 10 mg once daily.

Methods: This study was conducted in Çukurova University Hospital. Patients were enrolled between March 2005 and July 2006. Patients were manner to receive 10 mg of oral adefovir dipivoxil daily for 48 weeks. Virologic and biochemical assessments (serum HBV DNA and alanine aminotransferase [ALT] levels) were conducted every four weeks.

Results: The mean age of 36 patients was 34.8±10.3 years and 26 (72.2%) were male. Of the total, 32 (84%) had interferon and/or lamivudin treatment before administration. Of patients, 17 were HBeAg-negative and 19 were HBeAg-positive. Both the median of level of HBV DNA and median of ALT levels was significantly decreasing both in hepatitis B e antigen-positive and negative group during 48 weeks. The median change of HBV DNA was higher in HBeAg(+) group than HBeAg(-) group at every four weeks, however no significant differences between two groups at the end of 48 weeks. At the end of the 48 weeks, 28 of 36 (77.7%) patients had improvement in serum HBV DNA levels. Reductions in serum HBV DNA levels were 1.7, 2.3 and 2.7 log at 12th, 24th and 48th week respectively. Hepatitis B e antigen seroconversion rate in HBeAg(+) group was 15.8% (3/19). Treatment has been found to be safe and effective and well tolerated, with a low incidence of adverse events.

Conclusion: In patients with HBeAg-negative and positive chronic hepatitis B, 48 weeks of adefovir dipivoxil treatment resulted in significant virologic, and biochemical improvement.

Session Details

Date: 31/03/2007
Time: 00:00-00:00
Session name: European Society of Clinical Microbiology and Infectious Diseases
Subject:
Location: ICC, Munich, Germany
Presentation type:
Back to top